ELI LILLY & CO

Explore how Eli Lilly’s AI‑driven R&D and targeted acquisitions are reshaping its pipeline, cutting costs, and battling patent cliffs in a competitive pharma market.

Explore how Eli Lilly’s Medicare weight‑loss rollout, Centessa acquisition, and breakthrough oncology drug Jaypirca fuel a rally in defensive healthcare stocks.

Explore Eli Lilly’s dual obesity strategy: Retatrutide’s multi‑modal benefits vs. Foundayo’s oral GLP‑1 breakthrough, market‑access, patent, and M&A insights.

Discover how Eli Lilly’s new obesity drugs—retatrutide, Foundayo, and Zepbound—show Phase 3 promise for weight loss, diabetes and sleep apnea, reshaping the market.

Explore how Eli Lilly’s 50% cut to its Alzey plant and the $1.9 B partnership with Ascidian Therapeutics reshape its strategy, boost portfolio diversity, and secure long‑term growth.

Explore Eli Lilly’s latest shareholder moves, breakthrough obesity and oncology trials, and strategic bond issuance that strengthen its market position and future growth.

Explore how Eli Lilly’s breakthrough obesity drug retatrutide and its expanding oncology lineup, set to debut at ASCO 2026, are positioning the company for long‑term growth and investor confidence.

Read how Eli Lilly’s 2026 earnings forecast, Zepbound/Foundayo gains, and a $2.25 B gene‑editing partnership could boost investor confidence amid GLP‑1 competition.

Eli Lilly’s Q1 earnings will reveal if Foundayo’s slow GLP‑1 adoption and its $7 billion Kelonia CAR‑T deal can sustain growth and diversify revenue in 2024.

Explore how Eli Lilly’s weight‑loss drugs navigate the CMS “bridge program” and delayed BALANCE pilot, plus EMA procurement trends, to secure Medicare revenue and long‑term growth.